Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.


2024-12-22	0.9 -56.92 %
2023-12-31	2.08 309.11 %
2022-12-31	0.51 -55.12 %
2021-12-31	1.13 -72.25 %
2020-12-31	4.08 -6.8 %
2019-12-31	4.38 -79.32 %
2018-12-31	21.18 -169.11 %
2017-12-31	-30.65 -Infinity %

Helius Medical Technologies, Inc.

HSDT | NASDAQ Capital Market

As of 2024-12-22, Helius Medical Technologies, Inc.'s Price-to-Book (P/B) Ratio stood at 0.9, with a -56.92% variation.